Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elimination of chemoresistant myeloma clonogenic cells from human bone marrow by monoclonal antibody and complement.

Progress in clinical and biological research - 1 Jan 1990

Tong A W, Dalton W S, Tsuruo T, Fay J W, Stone M J

Abstract excerpt

We examined the effectiveness of a previously characterized plasma cell-reactive monoclonal antibody (MoAb), MM4, in eliminating multi-drug resistant (MDR1) multiple myeloma (MM) clonogenic colony-forming cells (CCCs). MDR1 sublines with 6-fold (RPMI8226/DOX6) and 40-fold (RPMI 8226/DOX40) resistance to doxorubicin (DOX) were selected from the chemosensitive MM parent line RPMI 8226/S. Both sublines remained...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Bone Marrow

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Bone Marrow Cells

Share to Cell Survival

Share to Drug Resistance

Share to Multiple Myeloma

Share to Phenotype

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 2308979

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elimination of chemoresistant myeloma clonogenic cells from human bone marrow by monoclonal antibody and complement.PMID 2308979Read ↗

Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells.Semantic proximity Read ↗

Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.Semantic proximity Read ↗

Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.Semantic proximity Read ↗

Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype.Semantic proximity Read ↗

A negative-selection strategy for depleting myeloma cells from patients' BM and/or leukapheresis blood.Semantic proximity Read ↗

Evidence for Cell Adhesion-Mediated Drug Resistance of Multiple Myeloma Cells in VivoSemantic proximity Read ↗

A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to DoxorubicinSemantic proximity Read ↗

Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828.Semantic proximity Read ↗

Murine monoclonal antibody recognizing a 90-kDa cell-surface determinant selectively lost by multi-drug-resistant variants of CEM cells.Semantic proximity Read ↗

Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells [see comments]Semantic proximity Read ↗

Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells [see comments]Semantic proximity Read ↗

Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug-resistant cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.